Figure 1From: CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patientsACPA level at baseline and 6 months following abatacept treatment. ACPA level was measured in serum of 33 RA patients undergoing abatacept therapy at baseline and 6 months following treatment. Samples ≥ 25 AU/mL are defined as positive.Back to article page